A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects. Two doses of the modified-release formulation and one dose of the immediate-release formulation will be evaluated under fasted conditions. One dose of the modified-release formulation will also be evaluated in the presence of food.

Key facts

Study ID

NCT01530529

Run by

Pfizer

People needed

12

Starts

2012-01-01

Expected to finish

2012-04-01

Last updated by the study team

2012-05-01

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female of non-childbearing potential

You may not qualify if…

• Evidence of clinically-significant medical illness, history of seizures, any condition possibly affecting drug absorption

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.